Individualized mutation detection in circulating tumor DNA for monitoring colorectal tumor burden using a cancer-associated gene sequencing panel

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Sato, Kei A ^a   Hachiya, Tsuyoshi ^a   Iwaya, Takeshi ^a   Kume, Kohei ^a   Matsuo, Teppei ^a   Kawasaki, Keisuke ^a   Abiko, Yukito ^a   Akasaka, Risaburo ^a   Matsumoto, Takayuki ^a   Otsuka, Koki ^a   Nishizuka, Satoshi S ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; ATM PROTEIN; B RAF KINASE; CD135 ANTIGEN; CIRCULATING TUMOR DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; JANUS KINASE 3; NOTCH1 RECEPTOR; NUCLEOPHOSMIN; PROTEIN KINASE LKB1; PROTEIN P53; PROTEIN RET; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; SMOOTHENED PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN RECEPTOR 2; PRIMER DNA;

ABL1 GENE; ADULT; AGED; AKT1 GENE; ALK GENE; APC GENE; ARTICLE; ATM GENE; BLOOD SAMPLING; BRAF GENE; CANCER CELL LINE; CDH1 GENE; CDKN2A GENE; CLINICAL ARTICLE; COLON CANCER CELL LINE; COLORECTAL CANCER; CONTROLLED STUDY; CSF1R GENE; CTNNB1 GENE; DNA EXTRACTION; DROPLET DIGITAL POLYMERASE CHAIN REACTION; EGFR GENE; ERBB2 GENE; ERBB4 GENE; EZH2 GENE; FBXW7 GENE; FEMALE; FGFR1 GENE; FGFR2 GENE; FGFR3 GENE; FLT3 GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GNA11 GENE; GNAQ GENE; GNAS GENE; HNF1A GENE; HRAS GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; JAK2 GENE; JAK3 GENE; KDR GENE; KIT GENE; MALE; MET GENE; MLH1 GENE; MPL GENE; NOTCH1 GENE; NPM1 GENE; NRAS GENE; ONCOGENE K RAS; PDGFRA GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PIK3CA GENE; POINT MUTATION; POLYMERASE CHAIN REACTION; PTEN GENE; PTPN11 GENE; RB1 GENE; RET GENE; SMAD4 GENE; SMARCB1 GENE; SMO GENE; SRC GENE; STK11 GENE; TP53 GENE; TUMOR GENE; TUMOR VOLUME; VHL GENE; ADENOCARCINOMA; ALLELE; BLOOD; CHEMISTRY; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DEVICES; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; GENETICS; MIDDLE AGED; MONONUCLEAR CELL; MULTIPLEX POLYMERASE CHAIN REACTION; PATHOLOGY; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGED; ALLELES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENES, NEOPLASM; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; TUMOR BURDEN;

EID: 84954052542     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146275     Document Type: Article

References (36)

1. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. doi: 10.1056/NEJMoa1213261 PMID: 23484797
2. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14(9):985-90. doi: 10.1038/nm.1789 PMID: 18670422
3. Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B. Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci U S A. 2014.
4. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013; 339(6127):1546-58. doi: 10.1126/science.1235122 PMID: 23539594
5. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486(7404):537-40. doi: 10. 1038/nature11219 PMID: 22722843
6. Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res. 2013; 19(12):3276-84. doi: 10.1158/1078-0432.CCR-12-3768 PMID: 23637122
7. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014; 20(6):1698-705. doi: 10.1158/1078-0432.CCR-13-2482 PMID: 24429876
8. Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A. Changes in mutational status during third-line treatment for metastatic colorectal cancer-results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer. 2014; 135(9):2215-22. doi: 10.1002/ijc.28863 PMID: 24659028
9. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012; 18(4):1177-85. doi: 10.1158/1078-0432.CCR-11-0564 PMID: 22228631
10. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012; 4 (136):136ra68. doi: 10.1126/scitranslmed.3003726 PMID: 22649089
11. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497(7447):108-12. doi: 10.1038/nature12065 PMID: 23563269
12. Elbeik T, Nassos P, Kipnis P, Haller B, Ng VL. Evaluation of the VACUTAINER PPT Plasma Preparation Tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA. J Clin Microbiol. 2005; 43(8):3769-71. PMID: 16081908
13. Salimnia H, Moore EC, Crane LR, Macarthur RD, Fairfax MR. Discordance between viral loads determined by Roche COBAS AMPLICOR human immunodeficiency virus type 1 monitor (version 1.5) Standard and ultrasensitive assays caused by freezing patient plasma in centrifuged becton-dickinson vacutainer brand plasma preparation tubes. J Clin Microbiol. 2005; 43(9):4635-9. PMID: 16145119
14. Yu J, Miller R, Zhang W, Sharma M, Holtschlag V, Watson MA, et al. Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. Pharmacogenomics. 2008; 9(10):1459-66. doi: 10.2217/14622416.9.10.1459 PMID: 18855534
15. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, et al. Clinical validation of a nextgeneration sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013; 15(5):607-22. doi: 10.1016/j.jmoldx.2013.05.003 PMID: 23810757
16. Dickinson BT, Kisiel J, Ahlquist DA, Grady WM. Molecular markers for colorectal cancer screening. Gut. 2015; 64(9):1485-94. doi: 10.1136/gutjnl-2014-308075 PMID: 25994221
17. Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science. 1987; 238(4824):193-7. PMID: 2889267
18. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-7. doi: 10.1038/nature11252 PMID: 22810696
19. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32 (6):579-86. doi: 10.1200/JCO.2012.45.2011 PMID: 24449238
20. Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One. 2012; 7(11):e47020. doi: 10.1371/journal.pone.0047020 PMID: 23144797
21. Spindler KL, Appelt AL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. Int J Cancer. 2014; 135(12):2984-91. doi: 10.1002/ijc.28946 PMID: 24798213
22. Brenner H, Kloor M, Pox CP. Colorectal cancer. The Lancet. 2014; 383(9927):1490-502.
23. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27(19):3109-16. doi: 10.1200/JCO.2008.20.6771 PMID: 19451431
24. Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011; 29(28):3768-74. doi: 10.1200/JCO.2011.36.4539 PMID: 21859995
25. Mutch MG. Molecular profiling and risk stratification of adenocarcinoma of the colon. J Surg Oncol. 2007; 96(8):693-703. PMID: 18081153
26. Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014; 311(3):263-70. doi: 10.1001/jama.2013.285718 PMID: 24430319
27. McArdle C. ABC of colorectal cancer: primary treatment-does the surgeon matter? BMJ. 2000; 321 (7269):1121-3. PMID: 11061734
28. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMID: 16258065
29. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003; 100(15):8817-22. PMID: 12857956
30. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. 2011; 108(23):9530-5. doi: 10. 1073/pnas.1105422108 PMID: 21586637
31. Narayan A, Carriero NJ, Gettinger SN, Kluytenaar J, Kozak KR, Yock TI, et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 2012; 72(14):3492-8. doi: 10.1158/0008-5472.CAN-11-4037 PMID: 22581825
32. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A. 2012; 109(36):14508-13. doi: 10.1073/pnas. 1208715109 PMID: 22853953
33. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011; 83 (22):8604-10. doi: 10.1021/ac202028g PMID: 22035192
34. Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 2009; 15(6):2076-84. doi: 10.1158/1078-0432.CCR-08-2622 PMID: 19276259
35. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A. 2008; 105(11):4283-8. doi: 10. 1073/pnas.0712345105 PMID: 18337506
36. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467(7319):1114-7. doi: 10.1038/nature09515 PMID: 20981102